secwatch.observer — SEC 8-K summary
======================================

Issuer:     InspireMD, Inc. (NSPR)
CIK:        0001433607
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0001493152-23-036981
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CMS expands carotid stenting coverage to asymptomatic/standard-risk patients; InspireMD supports
--------------------------------------------------------------------------------

- CMS final NCD extends CAS coverage to asymptomatic and standard-risk patients, expanding addressable market.
- InspireMD advancing CAS and TCAR programs in U.S. and E.U. using CGuard EPS stent system.
- C-GUARDIANS IDE trial completed enrollment; 30-day safety results at VIVA Nov 1, 2023; PMA filing anticipated H2 2024.
- CGuard EPS stent studied in nine clinical trials with >1,850 patients and over 40,000 real-world procedures.
- CEO says CMS decision will accelerate shift from open surgery to endovascular 'stent first' approach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1433607/000149315223036981/0001493152-23-036981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1433607/000149315223036981/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-036981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer